During the past decade, Eye Associates of New Mexico conducted 21 clinical trials. In the 10-year time frame, 21 clinical trials started and 14 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 13 clinical trials were completed. i.e. 185.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Eye Associates of New Mexico" #1 sponsor was "Jaeb Center for Health Research" with 5 trials, followed by "Hoffmann-La Roche" with 4 trials sponsored, "Genentech, Inc." with 3 trials sponsored, "Abbott Medical Optics" with 2 trials sponsored and "Apellis Pharmaceuticals, Inc." with 2 trials sponsored. Other sponsors include 6 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Eye Associates of New Mexico" #1 collaborator was "Regeneron Pharmaceuticals" with 4 trials as a collaborator, "National Eye Institute (NEI)" with 3 trials as a collaborator, "National Institutes of Health (NIH)" with 2 trials as a collaborator, "AbbVie" with 1 trials as a collaborator and "Genentech, Inc." with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Eye Associates of New Mexico" are "Diabetic Macular Edema" (6 trials), "Diabetic Retinopathy" (3 trials), "Geographic Atrophy" (3 trials), "Cataract" (2 trials) and "Astigmatism" (1 trials). Many other conditions were trialed in "Eye Associates of New Mexico" in a lesser frequency.

Most popular intervention types in "Eye Associates of New Mexico" are "Drug" (24 trials), "Other" (4 trials), "Device" (3 trials), "Genetic" (2 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Ranibizumab" (4 trials), "Sham Procedure" (4 trials), "Faricimab" (3 trials) and "Deferred aflibercept" (2 trials). Other intervention names were less common.

The vast majority of trials in "Eye Associates of New Mexico" are 26 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Eye Associates of New Mexico". undefined are not yet recruiting, 2 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 16 completed trials in Eye Associates of New Mexico, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Eye Associates of New Mexico, 0 "Phase 1" clinical trials were conducted, 12 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".